foxo4 dri senolytic peptide human trial 2024 Frontiers FOX04-DRI - Apollo Peptide Sciences
FOX04 DRI Apollo Peptide Sciences Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect Full article: Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics FOXO4 DRI part 1 #peptide #molecule #research #health #information The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 peptide targets myofibroblast ameliorates bleomycininduced pulmonary fibrosis in mice through ECMreceptor interaction pathway Han 2022 Journal of Cellular and Molecular Medicine Wiley Online Library
Pay in 4 interest-free payments of $5.61 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6




